Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change
12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model.
Significant strategic and operational progress
As global temperatures have gone up, so too have outbreaks of many infectious illnesses. Climate change has exacerbated 218 out of 375 conditions
31 August 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce
Regulatory approval gives green light for trial to proceed 20 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company
OneThree Biotech completes build and optimisation of AI model for RSV data – results to come in H2
Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Iron ore prices fell to their lowest weekly level since February, as a combination of China’s increasing virus restrictions and worsening real estate crisis prevented a recovery.
Update on POLB 001 Clinical Development